Assessment of Endoscopic Disease Activity in Ulcerative Colitis: Is Simplicity the Ultimate Sophistication?
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
S. Karger AG
Abstract
Background: Endoscopic remission is an increasingly recognized important therapeutic endpoint in the management of patients with UC. Summary: The Mayo Endoscopic Score (MES) remains the most common endoscopic index recommended in guidelines and widely used in clinical trials and in clinical practice. The MES is easy, simple, and practical but is suboptimal at providing an accurate depiction of segmental healing and/or at measuring a substantial but incomplete response across the spectrum of endoscopic inflammation. Other endoscopic scores have been proposed but have not received wide recognition or adoption. © 2021 The Author(s). Published by S. Karger AG, Basel.
Description
Keywords
Endoscopy, Mayo endoscopic score, Mucosal healing, Ulcerative colitis, Golimumab, Infliximab, Mesalazine, Prednisone, Tofacitinib, Ustekinumab, Vedolizumab, Adult, Case report, Clinical article, Clinical practice, Digestive system disease assessment, Disease severity, Extended modified score, Human, Ileocolonoscopy, Male, Middle aged, Modified mayo endoscopic score, Modified score, Practice guideline, Proctitis, Remission, Review, Scoring system, Uc colonoscopic index of severity, Uc endoscopic index of severity